A host of burgeoning fields in biomedicine — from personalized therapies and CRISPR gene editing to targeted tumor diagnostics — depend on the ability of labs to synthesize DNA on demand, cheaply and reliably.

Innovators in the field like San Francisco-based Twist Bioscience and Cambridge, Mass.-based Gen 9 use silicon wafers and microarrays to scale up the process, but are still using the same basic chemical techniques pioneered some 30 years ago. Now, a tiny ten-person startup in San Diego called Molecular Assemblies Inc. is nudging into the field with an entirely new process that uses enzymes instead of chemicals to create DNA. The technique was co-invented by one of the company’s founders, William Efcavitch, who also helped pioneered the chemical technique for synthesizing DNA that is in widespread use today.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy